NHI.no
Annonse
Informasjon

Føflekkreft - tilbake til hverdagen

For mange av dem som behandles for føflekkreft, er de praktiske konsekvensene små. Svulsten fjernes med et forholdsvis lite inngrep, og man trenger ikke legges inn på sykehus. Sykmelding er ofte heller ikke nødvendig. På mange måter går livet videre som om ingenting var skjedd.

Føflekkreft: Etter at man er behandlet for føflekkreft, bør man foreta kontroller - både hos lege og ved selvundersøkelser.

Sist oppdatert:

27. apr. 2022

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Melanom . Referanselisten for dette dokumentet vises nedenfor

  1. Gjersvik P, Roscher I. Melanom – ikke føflekkreft. Tidsskr Nor Laegeforen. 2018 Mar 19;138(6). Norwegian. PMID: 29557146. PubMed
  2. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne melanomer. Helsedirektoratet, sist oppdatert mai 2020. www.helsedirektoratet.no
  3. Kreftregisteret. Cancer in Norway 2019. Oslo: Kreftregisteret, 2020. www.kreftregisteret.no
  4. Ferlay J, Ervik M, Lam F et al. (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Accessed 21 Apr 2022. Available from: gco.iarc.fr
  5. Årsrapport 2018: Resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for melanom. Oslo: Kreftregisteret, 2019. ISBN: 978-82-473-0071-8 www.kreftregisteret.no
  6. Kottschade LA, Grotz TE, Dronca RS et al. Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol 2014; 37: 635-41. pmid:23563206 PubMed
  7. Wu S, Han J, Laden F, Qureshi AA. Long-term ultraviolet flux, other potential risk factors, and skin cancer risk: A cohort study. Cancer Epidemiol Biomarkers Prev 2014; 23: 1080. pmid: 24876226 PubMed
  8. Keim U, Gandini S, Amaral T et al. Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. Eur J Cancer. 2021 Dec;159:98-104. Epub 2021 Nov 3. PMID: 34742161. PubMed
  9. Pampena R, Kyrgidis A, Lallas A, et al. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. J Am Acad Dermatol 2017; 77: 938-45. pmid:28864306 PubMed
  10. Vourc'h-Jourdain M1, Martin L, Barbarot S. Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review. J Am Acad Dermatol 2013; 68(3): 493-8. pmid:23182059 PubMed
  11. Reddy KK, Farber MJ, Bhawan J et al. Atypical (dysplastic) nevi: outcomes of surgical excision and association with melanoma. JAMA Dermatol 2013; 149: 928-34. pmid:23760581 PubMed
  12. Ribero S, Zugna D, Osella-Abate S, et al. Prediction of high naevus count in a healthy UK population to estimate melanoma risk. Br J Dermatol 2015. pmid: 26479165 PubMed
  13. Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD008955. pmid: 23775773 PubMed
  14. Chen T, Fallah M, Försti A et al. Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas. JAMA Dermatol 2015; 151: 607. pmid:25671687 PubMed
  15. Wu S, Cho E, Li W et al. History of Severe Sunburn and Risk of Skin Cancer Among Women and Men in 2 Prospective Cohort Studies. Am J Epidemiol 2016; 183(9): 824-33. pmid:27045074 PubMed
  16. Gandini S, Doré JF, Autier P et al. Epidemiological evidence of carcinogenicity of sunbed use and of efficacy of preventive measures. J Eur Acad Dermatol Venereol. 2019 Mar;33 Suppl 2:57-62. PMID: 30811691. PubMed
  17. Gaudy-Marqueste C, Wazaefi Y, Bruneu Y et al. Ugly Duckling Sign as a Major Factor of Efficiency in Melanoma Detection. JAMA Dermatol 2017; 153: 279-84. pmid:28196213 PubMed
  18. Bhatt M, Nabatian A, Kriegel D, Khorasani H. Does an increased number of moles correlate to a higher risk of melanoma? Melanoma Manag. 2016 Jun;3(2):85-87. Epub 2016 May 19. PMID: 30190875 PubMed
  19. American Academy of Dermatology Ad Hoc Task Force for the ABCDEs of Melanoma. Early detection of melanoma: reviewing the ABCDEs. J Am Acad Dermatol. 2015 ;72(4):717-23. pmid: 25698455 PubMed
  20. Williams NM, Rojas KD, Reynolds JM et al. Assessment of Diagnostic Accuracy of Dermoscopic Structures and Patterns Used in Melanoma Detection: A Systematic Review and Meta-analysis. JAMA Dermatol. 2021 Aug 4. Epub ahead of print. PMID: 34347005. PubMed
  21. Tzellos T, Kyrgidis A, Mocellin S, Chan AW, Pilati P, Apalla Z. Interventions for melanoma in situ, including lentigo maligna. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No.: CD010308. pmid: 25526608 PubMed
  22. Utjés D, Malmstedt J, Teras J et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial. Lancet 2019; 394: 471-77. pmid:31280965 PubMed
  23. Kyrgidis A, Tzellos T, Mocellin S, Apalla Z, Lallas A, Pilati P, Stratigos A. Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma. Cochrane Database of Systematic Reviews 2015, Issue 5. Art. No.: CD010307. DOI: 10.1002/14651858.CD010307.pub2. The Cochrane Library
  24. Hao C, Tian J, Liu H et al. Efficacy and Safety of anti-PD-1 and anti-PD-1 Combined With anti-CTLA-4 Immunotherapy to Advanced Melanoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) 2017; 96: E7325. pmid:28658143 PubMed
  25. Long GV, Luke JJ, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2022. pmid:36265502 PubMed
  26. Larkin J, Chiarion-Seleni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015. pmid: 26027431 PubMed
  27. Long GV, Atkinson V, Lo S et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018; 19: 672-81. pmid:29602646 PubMed
  28. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015 May;16(5):522-30. pmid: 25840693 PubMed
  29. Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 2016; 375(19): 1845-55. pmid:27717298 PubMed
  30. Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD011123. DOI: 10.1002/14651858.CD011123.pub2. The Cochrane Library
  31. Long GV, Hauschild A, Santinami M et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017; 377: 1813-23. pmid:28891408 PubMed
  32. Spasojevic M, Mariathasan AB, Frich L et al.. Kreftbehandling med isolert ekstremitetsperfusjon. Tidsskr Nor Legeforen 2021. doi:10.4045/tidsskr.21.0194 DOI
  33. Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 2020; 585: 107-12. pmid:32728218 PubMed
  34. Rohaan MW, Borch TH, van den Berg JH, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022;387(23):2113-2125. PubMed
  35. US Preventive Services Task Force. Screening for skin cancer: US Preventive Services Task Force recommendation statement. JAMA 2023. PMID: 37071089 PubMed
  36. Johansson M, Brodersen J, Gøtzsche PC, Jørgensen KJ. Screening for reducing morbidity and mortality in malignant melanoma. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No.: CD012352. DOI: 10.1002/14651858.CD012352.pub2. Accessed 21 April 2022. The Cochrane Library
  37. Matsumoto M, Wack S, Weinstock MAet al. Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System. JAMA Dermatol. 2022 Apr 6:e220253. Epub ahead of print. PMID: 35385051 PubMed
  38. O'Shea SJ, Davies JR, Newton-Bishop JA. Vitamin D, vitamin A, the primary melanoma transcriptome and survival. Br J Dermatol 2016; 175: 30-4. pmid:27667313 PubMed
  39. Diehl JW, Chiu MW. Effects of ambient sunlight and photoprotection on vitamin D status. Dermatol Ther 2010; 23: 48-60. pmid:20136908 PubMed
  40. Calomarde-Rees L, García-Calatayud R, Requena Caballero C et al. Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma. JAMA Dermatol 2019.0069. pmid:31042264 PubMed
  41. Green AC, Baade P, Coory M et al. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol 2012; 30(13): 1462. pmid:22412152 PubMed
Annonse
Annonse